Chugai Pharmaceutical Co., Ltd.
https://www.chugai-pharm.co.jp/english/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chugai Pharmaceutical Co., Ltd.
Deal Watch: A Closer Look At Boehringer Ingelheim’s Partnering Strategy
Plus deals involving AbbVie/Ripple, Novo Nordisk/Korro Bio, Novo Nordisk/NanoVation, Bharat, Alopexx, Gilead/Genesis, Lilly/Genetic Leap, Contraline/Population Council, Proveca/Cessatech, Vivtex/Equillium and more.
Newron Weighs Up Partners Or M&A As Excitement Grows Over Antipsychotic
The Italian firm has received "several indications of interest" in evenamide, which is being prepped to go into Phase III for treatment-resistant schizophrenia.
Sandoz And Liquidia Triumph On Treprostinil
Sandoz and partner Liquidia have welcomed a US court decision which found that interference by United Therapeutics with the launch of their generic treprostinil injection rival to Remodulin caused the pair losses of more than $137m.
Evergreen With Envy: Halozyme’s Subcutaneous Conversions Grow As Rivals Hope To Break In
Halozyme’s Enhanze technology has now brought seven monoclonal antibodies, including Ocrevus and Tecentriq, from IV to subcutaneous delivery, but Alteogen and other high-concentration formulation players hope to join the party as Medicare pricing issues help drive interest.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Chugai Pharma Europe
- Chugai Pharma Taiwan Ltd.
- C&C Research Laboratories
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice